<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400852</url>
  </required_header>
  <id_info>
    <org_study_id>MNK14112096</org_study_id>
    <secondary_id>2017-004139-35</secondary_id>
    <nct_id>NCT03400852</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy</brief_title>
  <acronym>BRAVE</acronym>
  <official_title>A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Participants 4 to 8 Years of Age With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double blind, placebo controlled, multiple dose study to examine the
      safety and efficacy of MNK-1411 in male subjects 4 to 8 years of age (inclusive) with
      Duchenne Muscular Dystrophy (DMD).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment
  </why_stopped>
  <start_date type="Actual">July 17, 2018</start_date>
  <completion_date type="Actual">February 25, 2020</completion_date>
  <primary_completion_date type="Actual">February 25, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double blind (Investigator/Participant) The Care Provider and Outcomes Assessor were also blinded, but it is a double-blind trial.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>10 meter walk/run</measure>
    <time_frame>24 weeks</time_frame>
    <description>Motor performance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NorthStar Ambulatory Assessment</measure>
    <time_frame>24 weeks</time_frame>
    <description>Motor performance battery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4 stair climb</measure>
    <time_frame>24 weeks</time_frame>
    <description>Motor performance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rise from supine test</measure>
    <time_frame>24 weeks</time_frame>
    <description>Motor performance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative muscle testing</measure>
    <time_frame>24 weeks</time_frame>
    <description>Strength-knee flexion and extension measured in Newtons, using a dynamometer</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <arm_group>
    <arm_group_label>Treatment A, MNK1411 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cosyntropin suspension 0.5/0.4 mL for up to 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B, MNK1411 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cosyntropin suspension 0.25/0.2 mL for up to 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C, Placebo High Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo suspension 0.4/0.5 mL for up to 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D, Placebo Low Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo suspension 0.25/0.2 mL for up to 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cosyntropin</intervention_name>
    <description>Suspension administered subcutaneously twice weekly</description>
    <arm_group_label>Treatment A, MNK1411 High Dose</arm_group_label>
    <arm_group_label>Treatment B, MNK1411 Low Dose</arm_group_label>
    <other_name>MNK1411</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Suspension administered subcutaneously twice weekly</description>
    <arm_group_label>Treatment C, Placebo High Dose</arm_group_label>
    <arm_group_label>Treatment D, Placebo Low Dose</arm_group_label>
    <other_name>Matching Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants must have a documented diagnosis of Duchenne Muscular Dystrophy (DMD)
             confirmed by complete dystrophin deficiency (by immunofluorescence and/or immunoblot),
             or identifiable mutation in the DMD gene where reading frame can be predicated as &quot;out
             of frame,&quot; or complete dystrophin gene sequencing consistent with DMD; AND in the
             opinion of the Investigator, a typical clinical profile consistent with DMD.

          2. Participants taking approved treatments for DMD (by a Health Authority) that target
             dystrophin gene mutations (e.g., eteplirsen or ataluren) may be enrolled in the study
             if they have been on a stable dose for 30 days prior to the first dose of study drug,
             and plan to remain on that dose throughout the study.

        Exclusion Criteria:

          1. Participant has had previous systemic treatment with corticosteroids within 2 months
             prior to the Screening Visit. Exception: In subjects who were down-titrated to a
             physiological dose of corticosteroids (ie, 3mg/m2 of prednisone or deflazacort) a
             maximum of 1 month of no greater than a physiological dose followed by 1 month
             completely off corticosteroids prior to the Screening Visit will be acceptable for
             study entry. Transient previous use of corticosteroids will be evaluated on a
             case-by-case basis by the sponsor or designee. The use of topical or intra-articular
             corticosteroids is permitted during the study

          2. Participant is unable to complete the 10 meter Walk/Run test at the Screening and/or
             Baseline Visit.

          3. Participant has Type 1 or Type 2 diabetes mellitus.

          4. Participant has a history of chronic active hepatitis including acute or chronic
             hepatitis B, or acute or chronic hepatitis C.

          5. Participant has a history of tuberculosis (TB) infection, any signs/symptoms of TB, or
             any close contact with an individual with an active TB infection.

          6. Participant has known immune compromised status (not related to disease/condition
             under study), including but not limited to, individuals who have undergone organ
             transplantation or who are known to be positive for the human immunodeficiency virus.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Lead</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NW FL Clinical Research Group, LLC</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rare Disease Research, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Carell Jr Childrens Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Health Science Center, San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Aleksandrovska EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edith Wolfson Medical Center</name>
      <address>
        <city>H̱olon</city>
        <zip>5810001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele S.r.l. - PPDS</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Civil Fray Antonio Alcalde</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurociencias Estudios Clinicos S.C.</name>
      <address>
        <city>Culiacán</city>
        <state>Sinaloa</state>
        <zip>80020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Aplicadas a la Neurociencia A.C.</name>
      <address>
        <city>Durango</city>
        <zip>34000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Neurology and Psychiatry for Children and Youth</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu - PIN</name>
      <address>
        <city>Esplugues De Llobregat</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mersin Universitesi Tip Fakultesi Hastanesi</name>
      <address>
        <city>Mersin</city>
        <zip>33343</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Muscular Dystrophy</keyword>
  <keyword>DMD</keyword>
  <keyword>Duchenne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cosyntropin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

